WINDWARDNCT06475781
Study to Evaluate Safety and Efficacy of Mirivadelgat in PH-ILD (Windward)
StatusRecruiting
PhasePhase 2
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
Version history last read from ClinicalTrials.gov on Sep 22, 2026. The record was updated there on Nov 20, 2026; versions filed since then are not listed here yet.
All 14 versions: 14 with changes below. See every version on ClinicalTrials.gov ↗
- Minor Trial sites expanded: 11 → 15 locations
- Notable Eligibility criteria expanded, about 49 words
- Study sites: 9 to 11
- Secondary endpoints: details revised at 2 of 6 entries
- Notable Eligibility criteria expanded, about 135 words
- Study description shortened, about 16 words
- Minor Primary and study completion dates moved earlier to Feb 2028
- Site details revised at 7 of 9 sites
- Collaborator revised
- Study title expanded, about 1 word
- Notable Eligibility criteria expanded, about 2 wordsv11
Show 9 earlier versionsHide 9 earlier versions
- Minor Site details revised at 7 of 9 sitesv10
- Minor Study sites: 8 to 9v9
- Minor Site details revised at 1 of 8 sitesv8
- Minor Study sites: 7 to 8v7
- Minor Study sites: 6 to 7v6
- Minor Study sites: 4 to 6v5
- Notable Trial status: Not Yet Recruiting to Recruiting
- Start date changed from estimate of Apr 2025 to Mar 1, 2025
- Site details revised at 4 of 4 sites
- Notable Start date: Dec 2024 to Apr 2025
- Study sites: 0 to 4
- Minor Secondary endpoints: details revised at 3 of 6 entriesv2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Pulmonary Vascular Resistance (PVR)
Timeframe: 12 weeks
Secondary (6)
6-minute walk distance
Time to clinical deterioration from baseline to Week 12 for any of the following ADJUDICATED clinical events
Long-term prognostic risk factors
Patient-reported outcome measures (PROMS): (SF)-36v2
Patient-reported outcome measures (PROMS): WIQ
Show 1 moreShow less
Patient-reported outcome measures (PROMS): PAH-SYMPACT
Arms and interventions
150 mg mirivadelgatExperimental
150 mg mirivadelgat once daily
300 mg mirivadelgatExperimental
300 mg mirivadelgat once daily
placeboPlacebo comparator
placebo once daily
Drugs: Mirivadelgat, placebo
Sites
15 sites in 3 countries
Taiwan 9, Georgia 4, Bosnia and Herzegovina 2